Charles Schwab’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-355,296
| Closed | -$5.38M | – | 3599 |
|
|
2022
Q3 | $5.38M | Buy |
355,296
+7,275
| +2% | +$84.6K | ﹤0.01% | 2181 |
|
|
2022
Q2 | $2.61M | Buy |
348,021
+7,302
| +2% | +$51.5K | ﹤0.01% | 2478 |
|
|
2022
Q1 | $3.1M | Buy |
340,719
+15,737
| +5% | +$121K | ﹤0.01% | 2495 |
|
|
2021
Q4 | $2.28M | Buy |
324,982
+27,597
| +9% | +$289K | ﹤0.01% | 2664 |
|
|
2021
Q3 | $3.39M | Sell |
297,385
-18,267
| -6% | -$267K | ﹤0.01% | 2555 |
|
|
2021
Q2 | $5.05M | Buy |
315,652
+16,851
| +6% | +$289K | ﹤0.01% | 2350 |
|
|
2021
Q1 | $5.34M | Buy |
298,801
+13,945
| +5% | +$241K | ﹤0.01% | 2270 |
|
|
2020
Q4 | $3.85M | Buy |
284,856
+2,767
| +1% | +$33.4K | ﹤0.01% | 2347 |
|
|
2020
Q3 | $3.32M | Buy |
282,089
+15,706
| +6% | +$191K | ﹤0.01% | 2280 |
|
|
2020
Q2 | $3.93M | Buy |
266,383
+2,698
| +1% | +$39.9K | ﹤0.01% | 2135 |
|
|
2020
Q1 | $3.56M | Buy |
263,685
+5,291
| +2% | +$100K | ﹤0.01% | 2005 |
|
|
2019
Q4 | $6.25M | Buy |
258,394
+7,751
| +3% | +$161K | ﹤0.01% | 1910 |
|
|
2019
Q3 | $4.82M | Buy |
250,643
+15,730
| +7% | +$360K | ﹤0.01% | 1977 |
|
|
2019
Q2 | $6.94M | Buy |
234,913
+16,668
| +8% | +$642K | ﹤0.01% | 1814 |
|
|
2019
Q1 | $10.4M | Buy |
218,245
+12,359
| +6% | +$544K | 0.01% | 1564 |
|
|
2018
Q4 | $7.43M | Sell |
205,886
-1,327
| -0.6% | -$62.3K | 0.01% | 1656 |
|
|
2018
Q3 | $12.8M | Buy |
207,213
+7,554
| +4% | +$486K | 0.01% | 1471 |
|
|
2018
Q2 | $13.5M | Buy |
199,659
+17,314
| +9% | +$969K | 0.01% | 1386 |
|
|
2018
Q1 | $9.89M | Buy |
182,345
+17,740
| +11% | +$992K | 0.01% | 1506 |
|
|
2017
Q4 | $9.84M | Buy |
164,605
+11,937
| +8% | +$724K | 0.01% | 1487 |
|
|
2017
Q3 | $7.42M | Buy |
152,668
+14,379
| +10% | +$785K | 0.01% | 1653 |
|
|
2017
Q2 | $7.27M | Buy |
138,289
+2,183
| +2% | +$102K | 0.01% | 1569 |
|
|
2017
Q1 | $6.17M | Buy |
136,106
+1,388
| +1% | +$61.9K | 0.01% | 1634 |
|
|
2016
Q4 | $5.1M | Buy |
134,718
+29,050
| +27% | +$1.1M | 0.01% | 1726 |
|
|
2016
Q3 | $3.99M | Buy |
105,668
+68,124
| +181% | +$1.5M | ﹤0.01% | 1796 |
|
|
2016
Q2 | $661K | Buy |
37,544
+7,700
| +26% | +$125K | ﹤0.01% | 2495 |
|
|
2016
Q1 | $363K | Hold |
29,844
| – | – | ﹤0.01% | 2708 |
|
|
2015
Q4 | $727K | Hold |
29,844
| – | – | ﹤0.01% | 2499 |
|
|
2015
Q3 | $530K | Buy |
29,844
+200
| +0.7% | +$3.62K | ﹤0.01% | 2595 |
|
|
2015
Q2 | $524K | Buy |
29,644
+13,644
| +85% | +$250K | ﹤0.01% | 2660 |
|
|
2015
Q1 | $502K | Hold |
16,000
| – | – | ﹤0.01% | 2622 |
|
|
2014
Q4 | $468K | Hold |
16,000
| – | – | ﹤0.01% | 2644 |
|
|
2014
Q3 | $332K | Hold |
16,000
| – | – | ﹤0.01% | 2752 |
|
|
2014
Q2 | $397K | Buy |
16,000
+4,800
| +43% | +$83.1K | ﹤0.01% | 2734 |
|
|
2014
Q1 | $238K | Hold |
11,200
| – | – | ﹤0.01% | 2894 |
|
|
2013
Q4 | $202K | Buy |
+11,200
| New | +$146K | ﹤0.01% | 2954 |
|
Charles Schwab's AERI Position: Q4 2022 in Review
Charles Schwab sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 355,296 shares — an estimated $5.38M sold.
Charles Schwab first reported a position in AERI in Q4 2013 and held it in 36 quarters. The position peaked at $13.5M in Q2 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Charles Schwab reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Charles Schwab sold 355,296 Aerie Pharmaceuticals shares in Q4 2022, an estimated $5.38M.
- Charles Schwab first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 36 quarters.
- Charles Schwab's Aerie Pharmaceuticals position peaked at $13.5M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Charles Schwab's 13F filing for Q4 2022, filed 13 Feb 2023.